New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables ...
The first shipments of self-collection HPV tests for cervical cancer screening are making their way to labs and health care facilities across the United States. The Food and Drug Administration gave ...
Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...
The HPV self-collection solution allows an individual to collect their own vaginal sample for HPV screening while at a health care facility. The Food and Drug Administration (FDA) has approved Roche’s ...
The Food and Drug Administration approved the Roche cobas HPV Test to detect human papilloma virus through the use of cervical cells collected for a Pap test and stored in SurePath Preservative Fluid.
A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
There's a new way to screen for high-risk HPV, a viral infection that can lead to cervical cancer. This alternative method of collecting samples for cervical cancer screening doesn't require a ...
More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback